Related Experiment Video

Updated: Jun 27, 2025

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation
05:42

Z-Scores for Assessing Ovarian Reserve in Young Patients Undergoing Fertility Preservation

Published on: October 25, 2024

1.1K

The Australian New Zealand Consortium in Children, Adolescents, and Young Adults Oncofertility action plan

Lei Shong Lau1,2, Catherine Allingham1, Antoinette Anazodo3,4

  • 1Department of Obstetrics, Gynaecology and Newborn Health, Royal Women's Hospital, University of Melbourne, Parkville, Melbourne, Victoria, Australia.

Pediatric Blood & Cancer
|May 8, 2024
PubMed

Insights

This study describes current pediatric oncofertility practices in Australia and New Zealand. It proposes a 5-year action plan for the Australian New Zealand Consortium in Children, Adolescents, and Young Adults (CAYA) Oncofertility (ANZCO) to improve care.

Area of Science:

  • Reproductive medicine
  • Pediatric oncology
  • Health services research

Background:

  • International oncofertility networks have advanced care, but many countries lack a unified approach for pediatric patients.
  • Oncofertility services aim to preserve fertility in cancer patients undergoing gonadotoxic treatments.
  • Pediatric oncofertility is a critical component of survivorship care in adolescent and young adult oncology.

Purpose of the Study:

  • To describe baseline oncofertility practices in Australian and New Zealand pediatric hematology/oncology centers (2019-2021).
  • To identify binational priorities for pediatric oncofertility care.
  • To propose a 5-year action plan for the Australian New Zealand Consortium in Children, Adolescents, and Young Adults (CAYA) Oncofertility (ANZCO).

Main Methods:

  • Cross-sectional survey of Australian and New Zealand Children's Haematology/Oncology Group centers.
  • Analysis of current oncofertility service delivery models and patient pathways.
  • Consensus-building for future care priorities and strategic planning.

Main Results:

  • Baseline data on current oncofertility practices were collected from participating centers.
  • Key areas for improvement and binational priorities in pediatric oncofertility care were identified.
  • An action plan was developed to guide the implementation of best practices by ANZCO.

Conclusions:

  • Standardizing pediatric oncofertility care is essential across Australia and New Zealand.
  • The proposed 5-year action plan provides a roadmap for enhancing fertility preservation services for young cancer patients.
  • The newly formed ANZCO consortium is poised to lead the implementation of these improvements.

Keywords:
ANZCO action planchildren, adolescents and young adultsfertility preservationgonadal tissue preservationoncofertility care

More Related Videos

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

5.9K
Fertility Preservation in Patients with Severe Ovarian Dysfunction12:03

Fertility Preservation in Patients with Severe Ovarian Dysfunction

Published on: March 25, 2021

4.6K

Related Concept Videos

Infertility in Females01:28

Infertility in Females

Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
292
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
260
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K